on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy based on telomerase. Telomerase is the enzyme that controls the potential of cellular proliferation, and which is reactivated in 90% of human cancers (Nobel Prize 2009). So far, a major limitation in the development of an effective telomerase immunotherapy has been the technical impossibility to produce significant amount of telomerase protein, but recently a breakthrough system now allows its large-scale production (PMID: 25958399). Telomium implements this new technology which furthermore supports the preparation of a cancer vaccine of a completely new class in the pharmacopoeia: a ribonucleoprotein vaccine, which has the special ability to reproduce the mechanisms operating in autoimmunity that breaks immune tolerance. This self-adjuvanted and self-vectored telomerase ribonucleoprotein vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology. By inducing a full activation of the immune system against cells producing telomerase (=the cancer cells in an adult body), our product has the ability to induce an autoimmune reaction targeted against any form of cancer, without causing significant side effects. Given the almost universal presence of telomerase in human cancers our product has the potential to extend the efficiency of immune checkpoint-inhibitors from the current minority to a majority of patients.
At Karmagenes, we do behavioral genetic and psychological analysis to improve people’s personal and professional life. Karmagenes SA is a Swiss-based startup and its scientific team has developed proprietary algorithms that a) provide an unbiased view of genetic potential through DNA-based personality test, b) assess current personality through KG5+ psychological tool and c) offer custom advice through in-house psychologist regarding career orientation, partnership and wellbeing.
Since more than 450mio people have a bad mental being affecting their capacity ‘’to work and to love’’, our next step is to apply our technology to a life coaching app combining psychological and genetic data analysis coupled with artificial intelligence.
At your fingertip, you will have access to our existing network of coaches and specialists who can help you improve your overall wellbeing by understanding the real you.
Torreya Partners is a leading corporate finance advisory boutique serving companies in the life sciences industry.
Founded by Tim Opler and Mark Simon, Torreya has grown to have more than 50 professionals and a global presence in life sciences advisory. We have successfully completed more than 150 assignments since we started in August 2007.
Torreya has its primary offices in London, New York and Mumbai.
Our work has taken place in pharmaceuticals, biotechnology, medical technology, diagnostics, nutritionals, pharma services and closely related sectors. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks.
We are a partner of choice for companies seeking discreet, unconflicted and knowledgeable advice on M&A, corporate finance, licensing and asset sale transactions. In some cases, Torreya Partners acts as a pure advisor on a retained basis to its clients.
Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.
She has advised life sciences clients on more than 25 strategic transactions, valued at over
$65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients.
Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.
Nanna Lüneborg is a Principal at Novo Ventures, a leading global life science investor, which participated in the IPO of Inventiva in February 2017. Novo Ventures is part of Novo A/S, the holding and investment company of the Novo Nordisk foundation. Prior to joining Novo A/S, she was part of the life science investment team at Apposite Capital, a London-based venture capital firm specialising in healthcare. In 2012, she joined Novo A/S, where she has been part of both the seed and venture investment teams. She has previous board experience from a range of biotech companies spanning start-up to late stage development, most recently from the board of ObsEva, which completed an IPO on NASDAQ in January 2017. She currently serves on the boards of Orphazyme and Epsilon-3 Bio, in addition to Inventiva.
Nanna holds a BA from University of Oxford, a PhD in Neuroscience from University College London as a Wellcome Trust Scholar, and an MBA from University of Cambridge, where she was a Sainsbury Scholar.
Patrizia Marschalkova
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
At Dicronis, we are developing the first DIY lymphatic activity tracker, featuring a microneedles-covered patch and a wearable detector. The microneedles-mediated skin delivery of a fluorescent agent and the measure of its disappearance rate with a coupled wearable device allows for assessment of the dermal lymphatic function. Being minimally-invasive, painless and simple empower it to be used in a home setting by the patient, and accordingly, allow for a much better monitoring on the lymphatic health. This is highly relevant for basic or nutritional research purposes, to evaluate novel therapeutics or as diagnostic biomarker in diseases where this is disrupted, leading to debilitating consequences. For instance, lymphedema, a condition frequently occurring after cancer treatments, outlined by the swelling of a limb. Early diagnosis of the disease is highly crucial to ensure conservative measures, e.g. lymphatic draining massages or compression garments, are employed early-on for best management of the disease. Indeed, current methods of diagnosis of lymphedema are driven, by the clinical manifestation of the symptoms, which delay disease management and therefore worsen the prognosis.
Drooms AG is a leading European provider of secure cloud solutions. This software specialist facilitates highly secure access to confidential documents as well as the ability to safely exchange them with third parties beyond company firewalls. Confidential business processes, such as financing and licensing projects or Board Communication are handled securely, transparently and efficiently with Drooms. Headquartered in Frankfurt, Germany´s banking hub, Drooms is also expanding its global market presence and now has offices in Munich, London, Paris, Amsterdam, Zug, Madrid, Milan and Vienna. The company is well positioned to facilitate large-scale local and multi-jurisdictional transactions. Their professional expertise, top-tier reputation and innovative processes have laid the groundwork for a growing reputation in this market space. Selected References include Astellas, Hormosan, HRA Pharma, Novartis, NovImmune SA and Siemens.
Scailyte AG is an innovative Swiss-based company developing artificial intelligence (AI) technology for clinical research and diagnostics. We are offering a unique solution for the discovery of novel biomarkers for ultra-sensitive and early diagnosis of complex diseases such as cancer.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Retinitis Pigmentosa (RP), Leber’s Congenital Amaurosis (LCA) and Stargardt’s Disease (STGD) are rare eye diseases leading to severe vision impairment or blindness. Within the eye, they cause degeneration of the photoreceptors responsible for conversion of light into signals to be sent to the brain. The conditions are inherited and caused by ~250 different gene mutations. They affect a combined 450,000 people within the EU, Japan and the US. To date, no treatment is available for RP, LCA and STGD. Mireca wants to develop drug candidate LP–DF 003 which uses a novel approach for the treatment of the conditions. In contrast to current gene therapies, which address specific gene mutations, Mireca’s approach is significantly broader and assumed suitable to target at least one third of the various gene mutations. Based on the promising outcomes of the EU (FP7) funded DRUGSFORD project, Mireca benefits from completed pre-clinical pharmacology and initial safety testing, an existing orphan drug designation granted by the EMA, a GMP-compliant production process, 3 patent applications and exclusive licensing agreements. Beyond currently planned product developments, Mireca has access to a platform technology for the potential treatment of several neurodegenerative diseases. Mireca has been set up as a German limited liability company (“GmbH”) located in Tuebingen (~40 kilometers south of DE-Stuttgart). Mireca’s experienced international management team combines broad and deep scientific as well as business experience. Mireca wants to transition LP-DF003 into clinical studies and aims to obtain market authorizations for RP, LCA and STGD treatment products starting in the year 2024.
Responsive Web Design powered by 